Skip to main content

View full-text article in PMC

. 2021 May 25;32(6):1067–1077. doi: 10.1021/acs.bioconjchem.1c00123

Table 3. HIV inhibition by Peptide-Porphyrin Conjugates.

	IC₅₀ (μM)
Conjugates	MP-P3	MP-P5	P4-MP	MP-L-P3	P4-L-MP
100 TCDI₅₀	16.12 ± 1.3	33.1 ± 1.38	34.03 ± 1.25	16.59 ± 1.29	26.35 ± 1.24
10 TCDI₅₀^a	1.38 ± 1.1	10 ± 2.9	5.77 ± 1.17	1.985 ± 1.27	10.69 ± 1.33

Control	MP		PP
100 TCDI₅₀	>50		>50

^a

Approximate physiological conditions presented in a HIV brain infection.